<DOC>
	<DOCNO>NCT02658188</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety ASP8825 ( gabapentin enacarbil ) long-term treatment restless legs syndrome patient .</brief_summary>
	<brief_title>Long-term Efficacy Safety Gabapentin Enacarbil Japanese Restless Legs Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients diagnose RLS accord diagnostic criterion establish International RLS Study Group International Restless Legs Syndrome Scale ( IRLS ) score ≥15 presence RLS symptom ≥15 day per month ≥4 day per week precede inclusion study Patients use dopamine agonist gabapentin within 1 week antiRLS treatment within 2 week start pretreatment observation period Patients estimate creatinine clearance &lt; 60 mL/min determine use CockcroftGault formula Pregnant lactate woman Individuals serum ferritin &lt; 20 ng/mL also exclude trial Individuals movement disorder and/or abnormal neurological finding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Restless leg syndrome patient</keyword>
	<keyword>ASP8825</keyword>
	<keyword>XP13512</keyword>
</DOC>